We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Kinetics differences between PSA bounce and biochemical failure in patients treated with <sup>125</sup>I prostate brachytherapy.
- Authors
Hiromitsu Kanzaki; Masaaki Kataoka; Atsushi Nishikawa; Kotaro Uwatsu; Kei Nagasaki; Noriko Nishijima; Katsuyoshi Hashine
- Abstract
Objective: To determine the helpful factors to distinguish prostate-specific antigen failure from prostate- specific antigen bounce with large magnitude. Methods: From October 2004 to December 2009, 242 patients with prostate cancer treated with 125I brachytherapy were analyzed, 88 patients were excluded because the follow-up durations were shorter than 5 years. Their median follow-up was 80.4 months (60.0-123.9). Prostate-specific antigen failurewas determined using the Phoenix definition. Prostate-specific antigen bouncewas defined as an increase ≥0.2 ng/ml above the nadir, followed by a spontaneous return to the nadir. Prostatespecific antigen bounce +2 was defined as a prostate-specific antigen rise by 2.0 ng/ml or more above the nadir. Results: The 5-year biochemical relapse-free survival rate was 90.2%. Prostate-specific antigen failure and prostate-specific antigen bounce +2 were seen in 23 patients (14.9%) and 12 patients (7.8%), respectively. On univariate analysis, age at implant (P = 0.028), T stage (P = 0.020), time to prostatespecific antigen failure or prostate-specific antigen bounce (time to onset) (P = 0.0008), prostatespecific antigen velocity (P = 0.0003) and prostate-specific antigen doubling time (P = 0.0004) were significant for the distinction between prostate-specific antigen failure and prostate-specific antigen bounce +2. On multivariate analysis, no factor was the statistically significant factor. On receiver operating characteristic curve analysis, time to onset with a cutoff value of 29.8 months, prostate-specific antigen velocity of 0.18 ng/ml/month and prostate-specific antigen doubling time of 6.3 months had the highest accuracy of 82.9, 82.9 and 82.9% for prostate-specific antigen failure, respectively. Conclusions: Time to onset, prostate-specific antigen velocity and prostate-specific antigen doubling time would be helpful for distinction between prostate-specific antigen failure and prostatespecific
- Publication
Japanese Journal of Clinical Oncology, 2015, Vol 45, Issue 7, p688
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyv050